DAX 25.131 +0,0%ESt50 6.273 -0,2%MSCI World 4.851 +0,8%Top 10 Crypto 8,39 +2,5%Nas 26.207 +1,3%Bitcoin 56.267 +1,7%Euro 1,1424 -0,1%Öl 76,4 +0,7%Gold 4.098 -0,6%
Beliebte Suche
DAX 40ÖlpreisEuro - DollarBitcoin - EuroGoldpreis
Meistgesucht
BioNTech (ADRs)A2PSR2TeslaA1CX3TAmazon906866NEL ASAA0B733Microsoft870747Apple865985Siemens EnergyENER6YBASFBASF11NVIDIA918422Lufthansa823212Mercedes-Benz Group (ex Daimler)710000BayerBAY001Daimler TruckDTR0CKPlug PowerA1JA81TUITUAG00
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero.Hier informieren
Top News
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & MusterdepotsTools & integriertes TradingNewsletter, Trading-Desk uvm.
Schon einen Account? Anmelden

EQS-Adhoc: Symrise AG decides to divest its terpenes business and makes non-cash impairment. Symrise AG's investment in Swedencare AB is subject to a non-cash impairment.

Werte in diesem Artikel
Aktien
Symrise AG
88.40 EUR 0.52 EUR 0.59 %
Charts | News | Analysen
Aktie kaufen

EQS-Ad-hoc: Symrise AG / Key word(s): Miscellaneous
Symrise AG decides to divest its terpenes business and makes non-cash impairment. Symrise AG's investment in Swedencare AB is subject to a non-cash impairment.

12-Jan-2026 / 19:27 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

Werbung

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

 

Symrise AG decides to divest its terpenes business and makes non-cash impairment

Symrise AG's investment in Swedencare AB is subject to a non-cash impairment

 

Werbung

This publication contains two separate independent inside information.
 
  1. Symrise AG is in advanced talks with potential interested parties about the sale of its terpenes business. This is a structured bidding process. Based on the offers received so far, the international accounting standard IFRS 5 will be applied. In this context, a non-cash impairment charge of approximately EUR 145 million is recorded in the fourth quarter of 2025. This has a negative impact on Symrise AG's EBIT.
  2. According to preliminary calculations, a non-cash impairment in the value of the investment in Sweden-listed Swedencare AB will lead to a material deviation from the expected result for the 2025 financial year compared to current capital market expectations and the published forecast. Symrise AG will record a non-cash impairment charge of the investment in Swedencare AB in the amount of EUR 150 million in the fourth quarter of 2025. This has a negative impact on EBITDA. 
Neither measure has any impact on the liquidity and/or operating business of Symrise AG. They will be adjusted as part of the earnings reporting.
 

Media contact:                                               Investor Relations Contact
Bernhard Kott                                                  René Weinberg
Phone: +49 (0)5531 90-1721                           Phone: +49 (0)5531 90-1879
E-mail: bernhard.kott@symrise.com               E-mail: rene.weinberg@symrise.com
 


End of Inside Information

12-Jan-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

Language: English
Company: Symrise AG
Mühlenfeldstraße 1
37603 Holzminden
Germany
Phone: +49 (0)5531 90 0
E-mail: ir@symrise.com
Internet: www.symrise.com
ISIN: DE000SYM9999, DE000SYM7787, DE000SYM7704
WKN: SYM999
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2258790

 
End of Announcement EQS News Service
Werbung

2258790  12-Jan-2026 CET/CEST

Aktuelle Symrise Aktie News

Werbung

Symrise Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Symrise nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
02.07.26 Symrise Buy Deutsche Bank AG
29.06.26 Symrise Equal Weight Barclays Capital
18.06.26 Symrise Buy UBS AG
09.06.26 Symrise Overweight JP Morgan Chase & Co.
08.06.26 Symrise Neutral Goldman Sachs Group Inc.